This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailer, A J Articles by Dankovic, D A Search for Related Content PubMed PubMed Citation Articles by Bailer, A J Articles by Dankovic, D A Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

An introduction to the use of physiologically based pharmacokinetic models in risk assessment

Department of Mathematics and Statistics, Miami University, Oxford, Ohio, USA and National Institute for Occupational Safety and Health, USA

D A Dankovic

National Institute for Occupational Safety and Health, USA, ajbailer{at}muohio.edu

Many extrapolation issues surface in quantitative risk assessments. The extrapolation from high-dose animal studies to low-dose human exposures is of particular concern. Physiologically based pharmacokinetic (PBPK) models are often proposed as tools to mitigate the problems of extrapolation. These models provide a representation of the disposition, metabolism, and excretion of xenobiotics that are believed to possess the potential of inducing adverse human health responses. Given a model of xenobiotic disposition that is applicable for multiple species and appropriate for nonlinearity of the xenobiotic biotransformation process, better extrapolation may be possible. Unfortunately, the true structure of these models (e.g. number of compartments, type of metabolism, etc.) is seldom known, and attributes of these models (tissue volumes, partition coefficients, etc.) are often experimentally determined and often only central measures of these quantities are reported. We describe the use of PBPK models in risk assessment, the structural and parameter uncertainty in these models, and provide a simple illustration of how these characteristics can be incorporated in a statistical analysis of PBPK models. Additional complexity in the analysis of variability in the models is also outlined. This discussion is illustrated using data from methylene chloride.

Statistical Methods in Medical Research, Vol. 6, No. 4, 341-358 (1997)
DOI: 10.1177/096228029700600404


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Buur, R. Baynes, G. Smith, and J. Riviere Use of Probabilistic Modeling within a Physiologically Based Pharmacokinetic Model To Predict Sulfamethazine Residue Withdrawal Times in Edible Tissues in Swine. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2344 - 2351. [Abstract] [Full Text] [PDF]

				C. Portier and H. El Masri Statistical research needs in mechanistic modelling for carcinogenic risk assessment Statistical Methods in Medical Research, August 1, 1997; 6(4): 305 - 315. [Abstract] [PDF]